Medicenna Therapeutics (TSE:MDNA) Announces Earnings Results

Medicenna Therapeutics (TSE:MDNA) announced its quarterly earnings data on Thursday. The company reported C($0.06) EPS for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%.

Medicenna Therapeutics Trading Up 3.4%

Shares of TSE MDNA opened at C$0.61 on Friday. The firm has a market capitalization of C$50.89 million, a PE ratio of -4.07 and a beta of 2.84. Medicenna Therapeutics has a one year low of C$0.54 and a one year high of C$1.97. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30. The business has a 50-day moving average price of C$0.71 and a two-hundred day moving average price of C$0.99.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.